Seagull Health  |  CRISP
Assessment Date: May 28, 2026    Report ID: DSCA-2026-MO-0042
Demo Report — Fictitious Facility
Dementia-Seizure Conditions Assessment — Executive Summary
Maplewood Skilled Nursing & Rehabilitation  ·  Senior Care Investment  ·  Pre-Acquisition Review
Moderate-High
Exposure Characterization

Maplewood presents 2 Recognized Conditions and 4 Potential Conditions from the CMS public record, with 4 of 6 active conditions carrying High Recognition Risk — the tier mapped to DSS Domains 3 and 4, where seizure presentations are most frequently misattributed to dementia progression. The expected scenario projects approximately 6 residents with seizure/epilepsy comorbidity, rising to approximately 16 under stress assumptions applying early-onset AD prevalence rates. Subclinical epileptiform exposure — documented in 42–54% of AD patients without seizure history on extended EEG — may affect 12–21 additional residents at this facility who are entirely invisible to standard clinical documentation. Below-benchmark staffing at 3.4 hours/resident/day (11% below the national benchmark of 3.8) and 68% nursing staff turnover compound the recognition risk across DSS Domains 3 and 4 by reducing observational continuity and staff familiarity with individual residents' behavioral baselines.

What this assessment is
  • A structured pre-acquisition clinical-risk assessment built from publicly available records — CMS deficiency history, Five-Star component ratings, staffing data — and peer-reviewed literature; all sources disclosed by name
  • Data gaps treated as named findings, not disclaimers — each assigned a materiality tier and linked to the specific exposure estimates they affect, with explicit statements of what their absence means for due diligence
  • Transparent evidence grading: every clinical claim carries a basis type (Literature-Supported, Model-Extrapolated, or Expert Inference) disclosed in the evidence register
  • Honest about what the public record establishes and what it does not — including where facility-reported data has not been independently verified
What this assessment is not
  • Investment advice — this is the assessment's primary scope boundary; no go/no-go opinion is rendered and none should be inferred from any finding in this document
  • A clinical diagnosis or assessment of any individual resident — all findings are facility-level, derived from administrative and population-level data
  • A substitute for due-diligence record review — the named data gaps in Section 1 are this document's explicit scope limit, not fine-print disclaimers
  • A guarantee of outcomes — findings document conditions that exist in the public record; post-close results depend on actions taken by the acquiring entity
All facility names, resident identifiers, and transaction details are entirely fictitious and created for demonstration purposes only. This document is a clinical intelligence output — not investment advice, legal counsel, or a clinical assessment of any individual. Dementia Seizure Spectrum™ and SeizureSafe™ are trademarks of Seagull Health. © Seagull Health 2026.
Seagull Health  |  CRISP
Assessment Date: May 28, 2026    Report ID: DSCA-2026-MO-0042
Demo Report — Fictitious Facility
Dementia-Seizure Conditions Assessment — Executive Summary
Maplewood Skilled Nursing & Rehabilitation  ·  Senior Care Investment  ·  Pre-Acquisition Review
Assessment Summary — Four Sections
1
Recognized Seizure-Risk Conditions. 2 Recognized Conditions (F-689 fall-seizure nexus, F-658 professional standards) and 4 Potential Conditions (F-755 pharmacy management, F-740/741 behavioral health and staff competency, Five-Star component discrepancy, staffing profile); 1 Not Identified (Special Focus/enforcement history). 4 of 6 active conditions carry High Recognition Risk, mapping to DSS Domains 3 and 4 — awareness changes and behavioral manifestations indistinguishable from dementia fluctuation without structured protocols.
2
Population Exposure Estimate. Conservative scenario: ~3 residents (7.7% SNF-wide prevalence, Birnbaum et al. 2017). Expected scenario: ~6 residents (16% AD clinical prevalence, Vossel et al. 2013). Stress scenario: ~16 residents (40% EOAD prevalence, Haoudy et al. 2021). Subclinical epileptiform exposure — 42–54% of AD patients without seizure history on extended EEG (Vossel 2016; Horváth 2021) — may affect 12–21 additional residents entirely invisible to standard documentation; the literature indicates this exposure may exceed the clinically recognized population.
3
Evidence-Graded Risk Assessment. 8 clinical claims assessed: 5 Literature-Supported, 2 Model-Extrapolated (staffing-to-recognition-capacity, polypharmacy), 1 Expert Inference (F-740/741 misattribution mechanism). Synthesis conclusion: the convergence of F-740/741, below-benchmark staffing with high turnover, and F-658 citations produces a synergistic — not additive — recognition gap; each condition independently predicts the staff competency failure through which non-convulsive seizure presentations are misattributed to dementia progression.
4
Due Diligence Confirmation Items. Specific records, policies, and data points that would confirm, elevate, or reduce each active condition — named for F-689, F-658, F-755, F-740/741, and the staffing profile. All items are conditional: the exact record types that change each finding are stated, along with what their absence means for the operative planning estimate.
Named Data Gaps — Findings, Not Disclaimers
DG-1 Recognized GapPharmacy Records — available if requested. Eliminates ability to assess the tramadol/CYP2D6-inhibiting antidepressant combination associated with 6–9% elevated seizure incidence in SNF populations (Wei et al. 2025). Polypharmacy exposure in Section 2 is population-level inference only.
DG-2 Recognized GapMDS Data and Clinical Records — available if requested. Absence eliminates the primary mechanism for bounding tail exposure; the stress scenario (~16 residents) becomes the operative planning estimate by default when clinical records are not reviewed.
DG-3 Recognized GapSeizure Protocols and Staff Training — available if requested. Cannot assess whether the F-740/741 recognition risk finding has been partially addressed through internal measures; absence of documentation is consistent with — but does not confirm — the field-wide recognition gap.
DG-4 Potential GapState Licensing and Ombudsman Records — available independently (Missouri DHSS; MO LTC Ombudsman). May document conditions not yet reflected in the CMS public record; absence may understate Section 1 findings.
DG-5 Potential GapPending Enforcement and Litigation — available if requested; active litigation also obtainable through legal search. Absence does not constitute a clean record; requires explicit seller representation and a separate legal search.
Honest Scope
The 65% dementia census used throughout this assessment is facility-reported and has not been independently verified. All population exposure estimates in Section 2 scale proportionally with its accuracy; buyers should treat it as a management representation subject to MDS records verification. The subclinical epileptiform exposure — potentially affecting 12–21 residents — is a literature-bounded unknown: the exposure is not zero, the literature indicates it may exceed the clinically recognized population, and it cannot be bounded at the facility level without extended EEG data or clinical records review.
Exposure at a Glance
Facility / StateMaplewood SNF, Missouri
Licensed Beds60
Dementia Census65% (~39 residents) — facility-reported
CMS Five-Star Overall3/5  (Health Inspection: 2/5)
Nursing Turnover68%  (national avg. ~50%)
Staffing Hrs/Resident/Day3.4  (benchmark: 3.8)
Exposure CharacterizationMODERATE-HIGH
Conditions — Recognized / Potential2 Recognized  /  4 Potential
High Recognition Risk4 of 6 active conditions
Evidence Basis Distribution5 Lit-Supported / 2 Model / 1 Inference
Named Data Gaps3 Recognized  /  2 Potential
All facility names, resident identifiers, and transaction details are entirely fictitious and created for demonstration purposes only. This document is a clinical intelligence output — not investment advice, legal counsel, or a clinical assessment of any individual. Dementia Seizure Spectrum™ and SeizureSafe™ are trademarks of Seagull Health. © Seagull Health 2026.